Receipt date: 12/18/2007

1057781408-GAU: 1635

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10577814		
	Filing Date		2006-04-28		
INFORMATION DISCLOSURE	First Named Inventor Judy L		Lieberman		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1635		
(Not lot Submission under or of it 1.00)	Examiner Name				
	Attorney Docket Number		033393-055222		

	U.S.PATENTS Remove									
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	of cited Document		Releva	Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear	
	1	6228642	B1	2001-05	i-08	Baker et al.				
If you wish to add additional U.S. Patent citation information please click the Add button.										
			U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion		of cited Document		ges,Columns,Lines where levant Passages or Relevant ures Appear	
	1									
If you wis	h to ac	dd additional U.S. Publis	hed Ap	plication	citation	n information p	lease click the Add	d button	Add	
				FOREIC	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patented Applicant of cited Document	e or V F	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5
	1									
If you wis	h to ac	dd additional Foreign Pa	itent Do	cument	citation	information pl	ease click the Add	button	Add	•
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*  Cite Initials*  Cite No  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		

Receipt date: 12/18/2007	Application Number		10577814	10577814 - GAU: 1635	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2006-04-28		
	First Named Inventor	Judy l	Lieberman		
	Art Unit		1635		
	Examiner Name				
	Attorney Docket Number	er	033393-055222		
	·		•	·	

1	ASHKENAZI, A. and DIXIT, V.M. Science 281:1305-1308 (1998)	
2	CHIU & RANA, RNA 9:1034-1048 (2003)	
3	DEL ZOPPO, G.J., K.M.A. Welch, L.R. Caplan, D.J. Reis, et al., (Eds.) pp.217-220 Academic Press, San Diego (1997)	
4	FLOYD & CARNEY, Ann. Neurol. 32:S22-S27 (1992)	
5	GREEN, D.R. and EVAN, G.I. Cancer Cell 1:19-30 (2002)	
6	HAMADA et al., Antisense Nucleic Acid Drug Dev. 12:301-309 (2002)	
7	HERWEIJER & WOLFF, Gene Therapy 10:453-458 (2003)	
8	HEYMAN et al., Curr. Opin.Crit. Care. 8(6):526-34 (2002)	
9	JACKSON et al., Nat. Biotechnol. 21(6):635-637 (2003)	
10	LIU, K.D., Crit. Care Med. 31(8)(Suppl.):S572-S581 (2003)	
11	LEE et al., Am. J. Physiol. Heart Cicr. Physiol. 284:H456-H463 (2003)	

Receipt date: 12/18/2007	Application Number Filing Date		10577814	10577814 - GAU: 1635
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor  Art Unit	Judy	Lieberman	
	Examiner Name			
	Attorney Docket Numb	er	033393-055222	

12	LEWIS et al., Nature Genetics 32:107-108 (2002)	
13	MARUYAMA et al., J. Gene. Med. 4:333-341 (2002)	
14	MARUYAMA et al., Hum. Gene Ther. 13:455-468 (2002)	
15	MATTSON, M.P. Nat. Rev. Mol. Cell. Biol. 1:120-128 (2002)	
16	MCCAFFREY et al., Nature 418:38-39 (2002)	
17	MENÈ et al., J. Nephrol. 16:186-195 (2003)	
18	MEIER, P., et al., Nature 407:796-801 (2000)	
19	MOGI et al., Lab. Invest. 81(2):177-184 (2001)	
20	NAGATA & SUDA, Immunology Today 16(1):39-43 (1995)	
21	NANSEN et al., Blood 99(4):1237-1245 (2002)	
22	NOGAE et al., J. Am. Soc. Nephrol. 9(4):620-631 (1998)	

Receipt date: 12/18/2007	Application Number		10577814	10577814 - GAU: 1635	
INFORMATION BIOOLOGUEE	Filing Date		2006-04-28		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Judy I	Lieberman		
	Art Unit		1635		
	Examiner Name				
	Attorney Docket Number	er	033393-055222		

23	ORTIZ et al., Current Drug Targets – Immune, Endocrine & Metabolic Disorders 2:181-192 (2002)	
24	PASCHEN, W., J. Cereb. Blood Flow Metab. 23(7):773-779 (2003)	
25	PRAKASH et al., Ren. Fail. 25(2):225-233 (2003)	
26	RATHMELL, J.C. and THOMPSON, C.B. Cell 109 (Suppl.): S97-S107 (2002)	
27	REITER et al., Ann. N.Y. Acad. Sci. 993:35-47 (2003)	
28	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) Lancet, 347: 1398	
29	SATA & WALSH, J. Biol. Chem. 273(50):33103-33106 (1998)	
30	SCAFFIDI et al., J. Biol. Chem. 274(3):1541-1548 (1999)	
31	SLEDZ et al., Nat. Cell Biol. 5(9):834-839 (2003)	
32	SONG et al., Nat. Med. 9(3):347-351 (2003)	
33	SØRENSEN, Dag R. et al., J. Mol. Biol.; 327:761-766 (2003)	

Receipt date	: 12/18/2007	Application Number	10577814	105	577814 - (	GAU: 1635	
INFORMATION DISCLOSURE		Filing Date	2006-04-28				
		First Named Inventor	Judy Lieberman				
	T BY APPLICANT	Art Unit	1635				
( Not for submis	sion under 37 CFR 1.99)	Examiner Name					
		Attorney Docket Numb	er 033393-055222	<u> </u>			
34	TEOH & FARRELL, J. Gastroent	terol. Hepatol. 18:891-902 (20	003)				
35	THADHANI et al., N. Engl. J. Me	d. 334:1448-60 (1996)					
36	36 VAUX, D.L. and KORSMEYER, S.J. Cell 96:245-254 (1999)						
37	VERMUELEN, K., et al. Cell Prolif. 36:165-175 (2003)						
38	38 WALL, Nathan R. et al., The Lancet; 362:1401-1403 (2003)						
39	WATANABE-FUKUNAGA, R., et	al., J. Immunol., 148:1274-1.	279 (1992)				
40	ZHANG et al., Hum. Gene Ther.	10:1735-1737 (1999)					
41 2	ZHANG et al., J. Biol. Chem. 277	7(40):37430-37438 (2002)					
42	ZÖRNIG, M., et al., Biochim. Bio	phys. Acta 1551:F1-F37 (200	1)				
If you wish to add	l additional non-patent literatu	ure document citation infor	mation please click th	ne Add b	outton Add		
		EXAMINER SIGNAT	TURE				
Examiner Signati	ure /Sean Mcga	ırrv/	Date Consid	dered	09/28	/2009	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.